Amedeo Smart

Free Medical Literature Service

 

Amedeo

Multiple Sclerosis
  Free Subscription

Articles published in
J Neurol Neurosurg Psychiatry
    April 2025
  1. RUSKA B, Adamec I, Crnosija L, Gabelic T, et al
    Evolution of autonomic nervous system abnormalities in multiple sclerosis: a 6-year follow-up.
    J Neurol Neurosurg Psychiatry. 2025 Apr 24:jnnp-2024-335376.
    >> Share

  2. ZICCARDI S, Guandalini M, Crescenzo F, Martinelli L, et al
    Cluster analysis showed long-term cognition can be predicted by looking at regional grey matter atrophy in the first two years of multiple sclerosis course.
    J Neurol Neurosurg Psychiatry. 2025 Apr 23:jnnp-2025-335925.
    >> Share

  3. YAM C, Brownlee WJ, Prados Carrasco F, Toosy A, et al
    Investigating colour vision and its structural correlates 15 years following a first demyelinating event.
    J Neurol Neurosurg Psychiatry. 2025;96:435-442.
    >> Share

    March 2025
  4. SHIPLEY J, Beadnall H, Butzkueven H, van der Walt A, et al
    Impact of pregnancy on the maternal brain in health and multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2025 Mar 25:jnnp-2024-335319.
    >> Share

  5. MANOUCHEHRINIA A, Zhu F, Hillert J, McKay K, et al
    Prodromal phase of multiple sclerosis: evidence from sickness absence patterns before disease onset - a matched cohort study.
    J Neurol Neurosurg Psychiatry. 2025 Mar 25:jnnp-2024-335279.
    >> Share

  6. GELISSEN LMY, Toorop AA, Schipper PM, Hoitsma E, et al
    Low natalizumab trough concentrations are associated with reduced seroconversion of the John Cunningham virus in natalizumab-treated patients with multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2025 Mar 25:jnnp-2024-335761.
    >> Share

  7. GIORDANO A, Giliberti A, Clarelli F, Misra K, et al
    Sex hormone-related factors and the risk of PIRA in women with multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2025 Mar 13:jnnp-2024-335547.
    >> Share

  8. DZAU W, Roos I, Kalincik T
    Efficacy of natalizumab in secondary progressive multiple sclerosis: analysis of two phase III trials.
    J Neurol Neurosurg Psychiatry. 2025 Mar 6:jnnp-2024-335495.
    >> Share

  9. WINTER P, Axhausen F, Wolff S, Willison AG, et al
    Association of body mass index and clinical response in patients receiving ofatumumab for treatment of multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2025 Mar 6:jnnp-2024-335673.
    >> Share

  10. NOUI Y, Zjukovskaja C, Silfverberg T, Ljungman P, et al
    Factors associated with outcomes following autologous haematopoietic stem cell transplantation for multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2025 Mar 6:jnnp-2024-335512.
    >> Share

    February 2025
  11. JOHANSSON E, Guo J, Wu J, Olsson T, et al
    Impact of fish consumption on disability progression in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2025 Feb 25:jnnp-2024-335200.
    >> Share

  12. LAUERER M, Wiltgen T, Bruckner C, Engl C, et al
    Predictors of early disability accumulation in newly diagnosed multiple sclerosis: clinical, imaging and cerebrospinal fluid measures.
    J Neurol Neurosurg Psychiatry. 2025 Feb 17:jnnp-2024-335037.
    >> Share

  13. GUO J, Olsson T, Hillert J, Alfredsson L, et al
    Lifestyle factors associated with benign multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2025 Feb 13:jnnp-2024-335464.
    >> Share

    January 2025
  14. GOMBOLAY G, Johnson L, King R, Hebert M, et al
    Worldwide epidemiology of paediatric multiple sclerosis: data from the Multiple Sclerosis International Federation Atlas of MS, third edition.
    J Neurol Neurosurg Psychiatry. 2025 Jan 23:jnnp-2024-335175.
    >> Share

    December 2024
  15. DE ANGELIS F, Cameron JR, Eshaghi A, Parker R, et al
    Optical coherence tomography in secondary progressive multiple sclerosis: cross-sectional and longitudinal exploratory analysis from the MS-SMART randomised controlled trial.
    J Neurol Neurosurg Psychiatry. 2024 Dec 18:jnnp-2024-334801.
    >> Share

  16. DE MOL CL, Lamballais S, Muetzel R, Duijts L, et al
    Environmental multiple sclerosis (MS) risk factors, genetic MS risk, and brain development in a general paediatric population.
    J Neurol Neurosurg Psychiatry. 2024 Dec 10:jnnp-2024-335053.
    >> Share

  17. JEANTIN L, Bensa-Koscher C, Deschamps R, Gout O, et al
    Multiple sclerosis reactivations after fingolimod discontinuation for pregnancy planning.
    J Neurol Neurosurg Psychiatry. 2024 Dec 4:jnnp-2024-334629.
    >> Share

    October 2024
  18. RUBIN M, Preziosa P, Margoni M, Meani A, et al
    Dynamics of choroid plexus volume is associated with the presence and development of fatigue in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2024 Oct 10:jnnp-2024-334913.
    >> Share

    September 2024
  19. SCHOEPS VA, Bhargava P, Virupakshaiah A, Ladakis DC, et al
    Distinct plasma lipids predict axonal injury and multiple sclerosis activity.
    J Neurol Neurosurg Psychiatry. 2024 Sep 12:jnnp-2024-333652.
    >> Share

  20. ZARGHAMI A, Hussain MA, van der Mei I, Simpson-Yap S, et al
    Long-term disability trajectories in multiple sclerosis: a group-based trajectory analysis of the AusLong cohort.
    J Neurol Neurosurg Psychiatry. 2024 Sep 4:jnnp-2024-333632.
    >> Share

    August 2024
  21. GHEZZI L, Tosti V, Shi L, Cantoni C, et al
    Randomised controlled trial of intermittent calorie restriction in people with multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2024 Aug 13:jnnp-2024-333465.
    >> Share

    July 2024
  22. ANANTHAVARATHAN P, Sahi N, Chung K, Haider L, et al
    The evolving contribution of MRI measures towards the prediction of secondary progressive multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2024 Jul 22:jnnp-2024-333917.
    >> Share

  23. MIN YG, Moon Y, Kwon YN, Lee BJ, et al
    Prognostic factors of first-onset optic neuritis based on diagnostic criteria and antibody status: a multicentre analysis of 427 eyes.
    J Neurol Neurosurg Psychiatry. 2024;95:753-760.
    >> Share

  24. GIORDANO A, Clarelli F, Pignolet B, Mascia E, et al
    Vitamin D affects the risk of disease activity in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2024 Jul 14:jnnp-2024-334062.
    >> Share

  25. GOODIN DS
    Pathogenesis of multiple sclerosis: genetic, environmental and random mechanisms.
    J Neurol Neurosurg Psychiatry. 2024 Jul 2:jnnp-2023-333296.
    >> Share

    June 2024
  26. SHI L, Ghezzi L, Fenoglio C, Pietroboni AM, et al
    CSF sphingolipids are correlated with neuroinflammatory cytokines and differentiate neuromyelitis optica spectrum disorder from multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2024 Jun 6:jnnp-2024-333774.
    >> Share

  27. DAS J, Mallawaarachchi G, Grimshaw J, Jackson T, et al
    Ethnicity and deprivation negatively impact the access to disease-modifying therapy for relapsing-remitting multiple sclerosis: a retrospective, single-centre study.
    J Neurol Neurosurg Psychiatry. 2024 Jun 5:jnnp-2024-333338.
    >> Share

    May 2024
  28. NICHOLAS R, Tallantyre EC, Witts J, Marrie RA, et al
    Algorithmic approach to finding people with multiple sclerosis using routine healthcare data in Wales.
    J Neurol Neurosurg Psychiatry. 2024 May 23:jnnp-2024-333532.
    >> Share

  29. ROCCA MA, Valsasina P, Romano F, Tedone N, et al
    Cognitive rehabilitation effects on grey matter volume and Go-NoGo activity in progressive multiple sclerosis: results from the CogEx trial.
    J Neurol Neurosurg Psychiatry. 2024 May 16:jnnp-2024-333460.
    >> Share

  30. ENGLUND S, Frisell T, Qu Y, Gandhi K, et al
    Trajectories of self-reported fatigue following initiation of multiple sclerosis disease-modifying therapy.
    J Neurol Neurosurg Psychiatry. 2024 May 14:jnnp-2024-333595.
    >> Share

  31. VIRTANEN S, Piehl F, Frisell T
    Impact of previous treatment history and B-cell depletion treatment duration on infection risk in relapsing-remitting multiple sclerosis: a nationwide cohort study.
    J Neurol Neurosurg Psychiatry. 2024 May 14:jnnp-2023-333206.
    >> Share

  32. THIEL S, Litvin N, Haben S, Gold R, et al
    Disease activity and neonatal outcomes after exposure to natalizumab throughout pregnancy.
    J Neurol Neurosurg Psychiatry. 2024;95:561-570.
    >> Share

  33. MAAROUF A, Stellmann JP, Rico A, Boutiere C, et al
    Active and non-active progression independent of relapse activity within the first 20 years of relapsing multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2024 May 6:jnnp-2024-333597.
    >> Share

    April 2024
  34. ABDEL-MANNAN O, Champsas D, Tur C, Lee V, et al
    Evolution of brain MRI lesions in paediatric myelin-oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and its relevance to disease course.
    J Neurol Neurosurg Psychiatry. 2024;95:426-433.
    >> Share

  35. MAHLER MR, Magyari M, Pontieri L, Elberling F, et al
    Prognostic factors for disease activity in newly diagnosed teriflunomide-treated patients with multiple sclerosis: a nationwide Danish study.
    J Neurol Neurosurg Psychiatry. 2024 Apr 3:jnnp-2023-333265.
    >> Share

  36. DEKEYSER C, Hautekeete M, Cambron M, Van Pesch V, et al
    Routine CSF parameters as predictors of disease course in multiple sclerosis: an MSBase cohort study.
    J Neurol Neurosurg Psychiatry. 2024 Apr 3:jnnp-2023-333307.
    >> Share

    March 2024
  37. VERSTEGEN NJM, Hagen RR, Kreher C, Kuijper LH, et al
    T cell activation markers CD38 and HLA-DR indicative of non-seroconversion in anti-CD20-treated patients with multiple sclerosis following SARS-CoV-2 mRNA vaccination.
    J Neurol Neurosurg Psychiatry. 2024 Mar 28:jnnp-2023-332224.
    >> Share

  38. KALINCIK T, Sharmin S, Roos I, Massey J, et al
    Effectiveness of autologous haematopoietic stem cell transplantation versus natalizumab in progressive multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2024 Mar 27:jnnp-2023-332790.
    >> Share

  39. JONS D, Grut V, Bergstrom T, Zetterberg H, et al
    Seroreactivity against lytic, latent and possible cross-reactive EBV antigens appears on average 10 years before MS induced preclinical neuroaxonal damage.
    J Neurol Neurosurg Psychiatry. 2024;95:325-332.
    >> Share

  40. FOONG YC, Merlo D, Gresle M, Buzzard K, et al
    Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60.
    J Neurol Neurosurg Psychiatry. 2024 Mar 7:jnnp-2023-332883.
    >> Share

  41. JING J, Zhang Z, Su L, Gao C, et al
    Central vein sign and trigeminal lesions of multiple sclerosis visualised by 7T MRI.
    J Neurol Neurosurg Psychiatry. 2024 Mar 7:jnnp-2023-332566.
    >> Share

    February 2024
  42. POZZILLI V, Haggiag S, Di Filippo M, Capone F, et al
    Incidence and determinants of seizures in multiple sclerosis: a meta-analysis of randomised clinical trials.
    J Neurol Neurosurg Psychiatry. 2024 Feb 21:jnnp-2023-332996.
    >> Share

  43. IOANNIDIS JP
    Therapeutic interventions increasing seizure risk in multiple sclerosis: resolving discordant meta-analyses.
    J Neurol Neurosurg Psychiatry. 2024 Feb 21:jnnp-2024-333329.
    >> Share

    January 2024
  44. SIGNORI A, Ponzano M, Kalincik T, Ozakbas S, et al
    Emulating randomised clinical trials in relapsing-remitting multiple sclerosis with non-randomised real-world evidence: an application using data from the MSBase Registry.
    J Neurol Neurosurg Psychiatry. 2024 Jan 19:jnnp-2023-332603.
    >> Share

  45. JOHANSSON E, Alfredsson L, Strid P, Kockum I, et al
    Head trauma results in manyfold increased risk of multiple sclerosis in genetically susceptible individuals.
    J Neurol Neurosurg Psychiatry. 2024 Jan 11:jnnp-2023-332643.
    >> Share

    December 2023
  46. ELSBERND P, Cacciaguerra L, Krecke KN, Chen JJ, et al
    Cerebral enhancement in MOG antibody-associated disease.
    J Neurol Neurosurg Psychiatry. 2023;95:14-18.
    >> Share

  47. ZIVADINOV R, Pei J, Clayton D, Goldman DE, et al
    Evolution of atrophied T2 lesion volume in primary-progressive multiple sclerosis: results from the phase 3 ORATORIO study.
    J Neurol Neurosurg Psychiatry. 2023 Dec 6:jnnp-2023-332573.
    >> Share

    November 2023
  48. ALBA-ARBALAT S, Solana E, Lopez-Soley E, Camos-Carreras A, et al
    Predictive value of retinal atrophy for cognitive decline across disease duration in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2023 Nov 21:jnnp-2023-332332.
    >> Share

  49. KOCH M
    Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS).
    J Neurol Neurosurg Psychiatry. 2023 Nov 14:jnnp-2023-332758.
    >> Share

  50. TOOROP AA, van Lierop ZY, Gelissen LM, Hoitsma E, et al
    Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS).
    J Neurol Neurosurg Psychiatry. 2023 Nov 14:jnnp-2023-332119.
    >> Share

  51. FISSOLO N, Benkert P, Sastre-Garriga J, Mongay-Ochoa N, et al
    Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2023 Nov 8:jnnp-2023-332251.
    >> Share

  52. PALMER AJ, Zhao T, Taylor BV, van der Mei I, et al
    Exploring the cost-effectiveness of EBV vaccination to prevent multiple sclerosis in an Australian setting.
    J Neurol Neurosurg Psychiatry. 2023 Nov 2:jnnp-2023-332161.
    >> Share

    October 2023
  53. CAMPBELL JA, van der Mei I, Taylor BV, Palmer AJ, et al
    Using qualitative free-text data to investigate the lived experience of the COVID-19 pandemic for a large cohort of Australians with different multiple sclerosis related disability levels.
    J Neurol Neurosurg Psychiatry. 2023 Oct 26:jnnp-2022-330755.
    >> Share

  54. MONTINI F, Nozzolillo A, Tedone N, Mistri D, et al
    COVID-19 has no impact on disease activity, progression and cognitive performance in people with multiple sclerosis: a 2-year study.
    J Neurol Neurosurg Psychiatry. 2023 Oct 19:jnnp-2023-332073.
    >> Share

  55. MAIWORM M, Hamid C, Wagner M, Noth U, et al
    Multiparametric quantitative MRI reveals progressive cortical damage over time in clinically stable relapsing-remitting MS.
    J Neurol Neurosurg Psychiatry. 2023;94:786-791.
    >> Share

    September 2023
  56. RUGGIERI S, Prosperini L, Al-Araji S, Annovazzi PO, et al
    Assessing treatment response to oral drugs for multiple sclerosis in real-world setting: a MAGNIMS Study.
    J Neurol Neurosurg Psychiatry. 2023 Sep 29:jnnp-2023-331920.
    >> Share

  57. SILFVERBERG T, Zjukovskaja C, Ljungman P, Nahimi A, et al
    Haematopoietic stem cell transplantation for treatment of relapsing-remitting multiple sclerosis in Sweden: an observational cohort study.
    J Neurol Neurosurg Psychiatry. 2023 Sep 25:jnnp-2023-331864.
    >> Share

  58. YUSUF FLA, Asaf A, Marrie RA, Li P, et al
    Incidence and prevalence of paediatric-onset multiple sclerosis in two Canadian provinces: a population-based study representing over half of Canada's population.
    J Neurol Neurosurg Psychiatry. 2023 Sep 21:jnnp-2023-331991.
    >> Share

    August 2023
  59. GAY MC, Cassedanne F, Barbot F, Vaugier I, et al
    Long-term effectiveness of a cognitive behavioural therapy (CBT) in the management of fatigue in patients with relapsing remitting multiple sclerosis (RRMS): a multicentre, randomised, open-label, controlled trial versus standard care.
    J Neurol Neurosurg Psychiatry. 2023 Aug 30:jnnp-2023-331537.
    >> Share

  60. LONGINETTI E, Englund S, Burman J, Fink K, et al
    Trajectories of cognitive processing speed and physical disability over 11 years following initiation of a first multiple sclerosis disease-modulating therapy.
    J Neurol Neurosurg Psychiatry. 2023 Aug 9:jnnp-2023-331784.
    >> Share

  61. MASCARENAS-GARCIA M, Rivero-de-Aguilar A, Perez-Rios M, Ruano-Ravina A, et al
    Best practices in phase III clinical trials on DMTs for multiple sclerosis: a systematic analysis and appraisal of published trials.
    J Neurol Neurosurg Psychiatry. 2023 Aug 4:jnnp-2023-331733.
    >> Share

  62. HABEN S, Ciplea AI, Tokic M, Timmesfeld N, et al
    Early postpartum treatment strategies and early postpartum relapses in women with active multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2023 Aug 3:jnnp-2023-331525.
    >> Share

    July 2023
  63. LAUERER M, McGinnis J, Bussas M, El Husseini M, et al
    Prognostic value of spinal cord lesion measures in early relapsing-remitting multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2023 Jul 26:jnnp-2023-331799.
    >> Share

  64. KAPALI A, Daltveit AK, Myhr KM, Bjornevik K, et al
    Childbirth delivery mode and the risk of multiple sclerosis: a prospective population-based study.
    J Neurol Neurosurg Psychiatry. 2023 Jul 21:jnnp-2023-331241.
    >> Share

  65. JEANTIN L, Abdi B, Soulie C, Sterlin D, et al
    Is vaccine response to SARS-CoV-2 preserved after switching to anti-CD20 therapies in patients with multiple sclerosis or related disorders?
    J Neurol Neurosurg Psychiatry. 2023 Jul 21:jnnp-2023-331770.
    >> Share

  66. MOROZUMI T, Preziosa P, Meani A, Albergoni M, et al
    Influence of cardiorespiratory fitness and MRI measures of neuroinflammation on hippocampal volume in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2023 Jul 19:jnnp-2023-331482.
    >> Share

  67. COLATO E, Prados F, Stutters J, Bianchi A, et al
    Networks of microstructural damage predict disability in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2023 Jul 19:jnnp-2022-330203.
    >> Share

  68. ROSENKRANZ SC, Gutmann L, Has Silemek AC, Dorr M, et al
    Visual function resists early neurodegeneration in the visual system in primary progressive multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2023 Jul 11:jnnp-2023-331183.
    >> Share

  69. DZAU W, Sharmin S, Patti F, Izquierdo G, et al
    Risk of secondary progressive multiple sclerosis after early worsening of disability.
    J Neurol Neurosurg Psychiatry. 2023 Jul 6:jnnp-2023-331748.
    >> Share

  70. DIOUF I, Malpas CB, Sharmin S, Roos I, et al
    Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial.
    J Neurol Neurosurg Psychiatry. 2023 Jul 6:jnnp-2023-331499.
    >> Share

    June 2023
  71. MARTINEZ-HERAS E, Solana E, Vivo F, Lopez-Soley E, et al
    Diffusion-based structural connectivity patterns of multiple sclerosis phenotypes.
    J Neurol Neurosurg Psychiatry. 2023 Jun 15:jnnp-2023-331531.
    >> Share

  72. HOUZEN H, Kano T, Kondo K, Takahashi T, et al
    Prevalence, incidence and clinical features of neuromyelitis optica spectrum disorders in northern Japan.
    J Neurol Neurosurg Psychiatry. 2023;94:494-495.
    >> Share

    May 2023
  73. STRIJBIS EM, Coerver E, Mostert J, van Kempen ZLE, et al
    Association of age and inflammatory disease activity in the pivotal natalizumab clinical trials in relapsing-remitting multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2023 May 12:jnnp-2022-330887.
    >> Share

  74. SARASTE M, Matilainen M, Vuorimaa A, Laaksonen S, et al
    Association of serum neurofilament light with microglial activation in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2023 May 2:jnnp-2023-331051.
    >> Share

    April 2023
  75. NOVAK F, Bajwa HM, Coia JE, Nilsson AC, et al
    Low protection from breakthrough SARS-CoV-2 infection and mild disease course in ocrelizumab-treated patients with multiple sclerosis after three mRNA vaccine doses.
    J Neurol Neurosurg Psychiatry. 2023 Apr 25:jnnp-2022-330757.
    >> Share

  76. LEPPERT D, Watanabe M, Schaedelin S, Piehl F, et al
    Granulocyte activation markers in cerebrospinal fluid differentiate acute neuromyelitis spectrum disorder from multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2023 Apr 19:jnnp-2022-330796.
    >> Share

  77. HARDING-FORRESTER S, Roos I, Nguyen AL, Malpas CB, et al
    Disability accrual in primary and secondary progressive multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2023 Apr 17:jnnp-2022-330726.
    >> Share

  78. MOCCIA M, Affinito G, Fumo MG, Giordana R, et al
    Fertility, pregnancy and childbirth in women with multiple sclerosis: a population-based study from 2018 to 2020.
    J Neurol Neurosurg Psychiatry. 2023 Apr 17:jnnp-2022-330883.
    >> Share

    March 2023
  79. WU J, Olsson T, Hillert J, Alfredsson L, et al
    Influence of oral tobacco versus smoking on multiple sclerosis disease activity and progression.
    J Neurol Neurosurg Psychiatry. 2023 Mar 31:jnnp-2022-330848.
    >> Share

  80. MARGONI M, Preziosa P, Storelli L, Gueye M, et al
    Paramagnetic rim and core sign lesions in paediatric multiple sclerosis patients.
    J Neurol Neurosurg Psychiatry. 2023 Mar 29:jnnp-2022-331027.
    >> Share

  81. RIVERO-DE-AGUILAR A, Perez-Rios M, Ruano-Ravina A, Candal-Pedreira C, et al
    Evidence of publication bias in multiple sclerosis clinical trials: a comparative analysis of published and unpublished studies registered in ClinicalTrials.gov.
    J Neurol Neurosurg Psychiatry. 2023 Mar 28:jnnp-2023-331132.
    >> Share

  82. LEADBETTER R, MacAskill M, Myall DJ, Taylor BV, et al
    Multiple sclerosis mortality in New Zealand: a nationwide prospective study.
    J Neurol Neurosurg Psychiatry. 2023 Mar 7:jnnp-2022-330582.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016